High expression of ETV4 predicted poorer progression-free interval for GBMLGG, ACC, MESO, PCPG, LGG, and cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), and better progression-free interval for ovarian serous cystadenocarcinoma (Figures 2C, 3C). Here, ETV4 is linked to ovarian serous cystadenocarcinoma.